Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).
— with sequence listing part of description (Rule 5.2(a))
IMMUNOLOGICAL COMPOSITIONS FOR HIV

Related Applications

This application claims priority to U.S. Ser. No. 61/243,522 filed September 7, 2008.

5 Field of the Invention

The present invention relates generally to the field of immunology and, in particular to methods and compositions for immunizing and generating protection in a host against infection and disease with HIV.

10 Background of the invention

Human immunodeficiency virus (HIV) is a human retrovirus and is the etiological agent of acquired immunodeficiency syndrome (AIDS). Despite the passage of more than 20 years since the discovery of HIV, no effective vaccine has been found to either ameliorate the disease or to prevent infection. By the end of the year 2007, more than 30 million people worldwide were infected with HIV, with more than 20 million of those people living in sub-Saharan Africa (Report on the Global AIDS Epidemic, Joint United Nations Programme on HIV/AIDS (UNAIDS), 2008).

A hallmark of resistance to future viral infection is the generation of 'neutralizing antibodies' capable of recognizing the viral pathogen. Another measure is cellular immunity against infected cells. In typical viral infections, generation of neutralizing antibodies and cellular immunity heralds recovery from infection. In HIV-1 infection, however, neutralizing antibodies and cellular immunity appear very early during the infection and have been associated with only a transient decrease in viral burden. In spite of the generation of neutralizing antibodies and cellular immunity, viral replication in HIV-1 infection rebounds and AIDS (acquired immune deficiency syndrome) develops. Thus, in HIV-1 infection, neutralizing antibodies and cellular immunity are not accurate measures of protective immunity. Protective immunity, meaning the vaccinees are protected against new infections by HIV, is a major unaccomplished goal of those skilled in the art.

Several potential vaccines have been tested in humans but found not to be protective. For examples, polypeptide vaccines based on gp120 have been tested (e.g., AIDSVAX* B/B, AIDSVAX* B/E (Vaxgen)) as solo vaccines or together in a prime-boost format, but have not
shown protection against HIV infection (McCarthy, M. Lancet. 362(9397): 1728 (2003); Nitayaphan, et al. J. Inf. Dis. 190:702-6 (2004); Pitisuttithum, P. 11* Conf. Retr. Opp. inf. 2004. 115: Abstract 107). Many studies have also been performed using animal models (e.g., monkeys). However, while primate data are instructive they also highlight the gaps in our understanding of immunological mechanism that mediate vaccine associated protection and emphasize the need to conduct human efficacy studies to test promising candidate vaccines empirically.

ALVAC-HIV (vCP1521) vaccine is a preparation of recombinant canarypox-derived virus expressing the products of the HIV-1 retrovirus genes. The genes are inserted into the ε 6 locus under the control of the vaccinia virus H6 and β L promoters respectively. The gp120 env sequence is derived from the HIV-92TH023 (subtype E) strain, but the anchoring part of gp41 is derived from the HIV-LAI (subtype B) strain. ALVAC-HIV infected cells present env and gag proteins in a near-native conformation (Fang, et al., J. Infect. Dis. 180 (4): 122-32 (1999)). In addition, intracellular processing of the HIV-1 proteins via the MEC class I pathway facilitates stimulation of cytotoxic T-lymphocytes. Part of the rationale for use of Gag from a subtype B in Thailand is that portions of the gag gene are conserved among virus subtypes. Therefore, gwg-specific CTL elicited by vCP1521 may cross-react with CTL epitopes on non-subtype B primary viruses. Data from an AVEG-sponsored prime-boost trial (vCP205 alone or boosted with Chiron SF2 gp20/MF59) showed that CDS° CTL from some vaccine recipients recognized target cells infected with non-subtype 8 vinises, including subtype E (Ferrari, et al Proc. Natl. Acad. Sci. USA, 94;1396-401 (1.997)).

In view of this data, several attempts have been made to provide protection using a prime-boost immunization format (McNeil, et al. Science. 303:961 (2004)). For example, AIDSVAX® B/E (VaxGen) and ALVAC-HIV have been used as the prime and boost compositions, respectively, and shown to induce neutralizing antibodies (Karnasuta, et al. Vaccine, 23: 2522-2529 (2005), in one safety trial, neutralizing antibodies were observed in 84% to 100% of subjects, cytotoxic lymphocytes (CTL) were observed in 16-25% of subjects, and lymphoproliferation was observed in 55-93% of subjects. In another safety trial, neutralizing antibodies were observed in 31% to 71% of subjects, cytotoxic lymphocytes (CTL) were observed in about 25% of subjects, and lympho-proliferation was observed in 58-71% of subjects. However, protection against infection by HIV was not shown, leading some to question the value of such a
combination vaccine (Burton, et al. Science. 303; 316 (2004); Letters to the Editor. Science. 305; 177-180 (2004)).

To date, no vaccine has shown protection against HIV infection. Thus, there is a clear need in the art for compositions and methods for protectively immunizing humans against HIV. Such compositions and methods are provided by this disclosure.

**Brief Description of the Drawings**

Figure 1. Comparison of the predicted amino acid sequence for A244 rgp120/HIV-1 protein (gd244) with the predicted sequence for MN rgp120/HIV-j protein (MN \textit{nature}).

Figure 2. A. Map of ALVAC-HTV (\textit{vCP1521}) genome. B. Nucleotide sequence of the HIV insert contained within ALVAC-HIV (\textit{vCP1S21}).

**Figure 3.** Efficacy of the ALDSVAX+ B/E / ALVAC-HIV prime-boost vaccine.

**Summary of the Invention**

The reagents and methodologies described herein may be used to protectively immunize a human being against human immunodeficiency virus, which has not been previously demonstrated. In one embodiment, a two-part composition including a first composition comprising an expression vector encoding an HIV immunogen, and a second composition comprising a polypeptide derived from or representing an HIV immunogen is provided. As shown herein, administration of the first composition prior to the second composition, and then administering the first and second compositions, protects human beings against infection by HIV. In an exemplary embodiment, the first composition includes a live, attenuated viral vector encoding at least one HIV immunogen, and the second composition includes an HIV immunogen in the form of a polypeptide. In certain embodiments, a method for protectively immunizing a human being against human immunodeficiency vims (HIV) by administering to the human being a vaccine composition. The composition consists essentially of a first composition and a second composition, the first composition consisting essentially of a live, attenuated avipox (e.g., canarypox, ALVAC) vector encoding multiple HIV imm\textup{unogens}, and the second
composition including one or more polypeptides corresponding in amino acid sequence to at least a portion of HIV gp120. In some embodiments, at least one of the compositions comprises an amino acid sequence corresponding to that of HIV and at least one amino acid sequence corresponding to a herpes simplex virus (HSV). In some embodiments, the first composition is administered to the human being and the first and second compositions are subsequently administered to the human being. In certain embodiments, the compositions are administered via the intramuscular route. Using this method, it has been found for the first time that human beings may be protected from infection by HIV. In certain embodiments, the method involves administering the vaccine to a population of human beings and at least about one-third of that population is protected from infection by HIV.

**Detailed Description**

The present invention provides compositions and methodologies useful for treating and / or preventing conditions relating to an infectious or other agent(s) such as a tumor cell by stimulating an immune response against such an agent. In general the immune response results from expression of an immunogen derived from or related to such an agent following administration of a nucleic acid vector encoding the immunogen, for example. In certain embodiments, multiple immunogens (which may be the same or different) are utilized. In other embodiments, variants or derivatives (i.e., by substitution, deletion or addition of amino acids or nucleotides encoding the same) of an immunogen or immunogens (which may be the same or different) may be utilized.

An immunogen may be a moiety (e.g., polypeptide, peptide or nucleic acid) that induces or enhances the immune response of a host to whom or to which the immunogen is administered. An immune response may be induced or enhanced by either increasing or decreasing the frequency, amount, or half-life of a particular immune modulator (e.g., the expression of a cytokine, chemokine, co-stimulatory molecule). This may be directly observed within a host cell containing a polynucleotide of interest (e.g., following infection by a recombinant virus) or within a nearby cell or tissue (e.g., indirectly). The immune response is typically directed against a target antigen. For example, an immune response may result from expression of an immunogen in a host following administration
of a nucleic acid vector encoding the immunogen to the host. The immune response may result in one or more of an effect (e.g., maturation, proliferation, direct- or cross-presentation of antigen, gene expression profile) on cells of either the innate or adaptive immune system. For example, the immune response may involve, effect, or be detected in innate immune cells such as, for example, dendritic cells, monocytes, macrophages, natural killer cells, and/or granulocytes (e.g., neutrophils, basophils or eosinophils). The immune response may also involve, effect, or be detected in adaptive immune cells including, for example, lymphocytes (e.g., T cells and/or B cells). The immune response may be observed by detecting such involvement or effects including, for example, the presence, absence, or altered (e.g., increased or decreased) expression or activity of one or more immunomodulatory such as a hormone, cytokine, interleukin (e.g., any of IL-1 through IL-35), interferon (e.g., any of IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-τ, IFN-ζ, IFN-ω), IFN-II (e.g., IFN-γ), IFN-III (IFN-λ1, IFN-λ2, IFN-λ3), chemokines (e.g., any CC cytokine (e.g., any of CCL1 through CCL28), any CXC chemokine (e.g., any of CXCL1 through CXCL24), MIP-1α), any C chemokine (e.g., XCL1, XCL2), any CX3C chemokine (e.g., CX3CL1), tumor necrosis factor (e.g., TNF-α, TNF-β), negative regulators (e.g., PD-1, IL-T) and/or any of the cellular components (e.g., kinases, lipases, nucleases, transcription-related factors (e.g., IRF-1, IRF-7, STAT-5, NFκB, STATS, STAT1, IRF-10), and/or cell surface markers suppressed or induced by such immunomodulators) involved in the expression of such immunomodulators. The presence, absence or altered expression may be detected within cells of interest or near those cells (e.g., within a cell culture supernatant, nearby cell or tissue in vitro or in vivo, and/or in blood or plasma). Administration of the immunogen may induce (e.g., stimulate a de novo or previously undetected response), or enhance or suppress an existing response against the immunogen by, for example, causing an increased antibody response (e.g., amount of antibody, increased affinity/avidity) or an increased cellular response (e.g., increased number of activated T cells, increased affinity/avidity of T cell receptors, cytotoxicity including but not limited to antibody-dependent cellular cytotoxicity (ADCC), proliferation). In the case of HIV infections, no clear correlates of immunity have been associated with immunity (especially protective immunity), but any of the measures described herein may be helpful in determining the usefulness of the
compositions and methods described herein. Some immune responses may, in the case of a viral immunogen, lead to decreased viral load in, or bad to elimination of the virus from a host. In certain embodiments, the immune response may be protective, meaning that the immune response may be capable of preventing initiation or continued infection of or growth within a host and/or by eliminating an agent (e.g., a causative agent, such as HIV) from the host. In some instances, elimination of an agent from the host may mean that the vaccine is therapeutic. In some embodiments, a composition comprising an immunogen may be administered to a population of hosts (e.g., human beings) and determined to provide protective immunity to only a portion of that population. The composition may therefore be considered to protect a portion of that population (e.g., about 1/10, 1/4, 1/3, 1/2, or 3/4 of the population). The proportion of the population that is protected may be calculated and thereby provide the efficacy of the composition in that population (e.g., about 10%, 25%, 33%, 50%, or 75% efficacy).

With respect to HIV, immunogens may be selected from any HIV isolate (e.g., any primary or cultured HIV-1, HIV-2, and/or HIV-3 isolate, strain, or clade). As is well-known in the art, HIV isolates are now classified into discrete genetic subtypes. HIV-1 is known to comprise at least ten subtypes (A1, A2, A3, A4, B, C, D, E, P, L, F2, G, H, j, and K) (Taylor et al., NEJM, 359(18):1965-1966 (2008)). HIV-2 is known to include at least five subtypes (A, B, C, D, and E). Subtype B has been associated with the HIV epidemic in homosexual men and intravenous drug users worldwide. Most HIV-1 immunogens, laboratory adapted isolates, reagents and mapped epitopes belong to subtype B. In sub-Saharan Africa, India, and China, areas where the incidence of new HIV infections is high, HIV-1 subtype B accounts for only a small minority of infections, and subtype HIV-1 C appears to be the most common infecting subtype. Thus, in certain embodiments, it may be preferable to select immunogens from particular subtypes (e.g., HIV-1 subtypes B and/or C), it may be desirable to include immunogens from multiple HIV subtypes (e.g., HIV-1 subtypes A and B, or a combination of HIV-1, HIV-2, and/or HIV-3 subtypes) in a single immunological composition. Suitable HIV immunogens include HIV envelope (env; e.g., NCBI Ref. Seq. NP_057856, or as shown in any of Figs. 1, 2 and/or SEQ ID NOS. 1-6), gag (e.g., p6, p7, p17, p24, GenBank AAD39400.1), the protease encoded by pol (e.g., UniProt P03366), nef (e.g.,
Ce nBank CAA 41585.1; Shugas, et al. J. ViroL Aug. 1993, pp. 4639-4650 {1993}). as well as variants, derivatives, and Fusion proteins thereof as described by, for example, Gomez et al. Vaccine, Vol. 25, pp. 1969-1992 (2007). Inmunogens (e.g., env and pol) may be combined as desired. Inmunogens from different HIV isolates (e.g., HIV-1 A1 env and HIV-1 42 env) may also be combined (e.g., AIDSVAX B/B™ and AIDSVAX T™ B/E). In some embodiments, at least one of the compositions comprises an amino acid sequence corresponding to that of HIV and at least one amino acid sequence corresponding to a herpes simplex vims (HSV). In some embodiments, the HSV antigen may be the glycoprotein D (gD) leader sequence shown in Fig. 1. In certain embodiments, the HSV amino acid sequence comprises KYALADASLMADPNRFRGKDLPDQL (SEQ ID NO. 7), or a fragment or derivative thereof. In some embodiments, at least one of the compositions comprises SEQ ID NO. 7. In some embodiments, a suitable immunogen may be the polypeptide gd244 as shown in Fig. 1, or a fragment thereof. In others, a suitable immunogen may be the polypeptide "MN.mature" shown in Fig. 1, or a fragment thereof. Suitable strains and combinations may be selected by the skilled artisan as desired.

In some embodiments, a method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the human being at least one dose of a first composition comprising a viral vector encoding an HIV polypeptide or fragment or derivative thereof and subsequently administering to the human being at least one dose of a second composition comprising the HIV polypeptide or fragment or derivative thereof, wherein a protective immune response directed against HIV results, is provided. In some embodiments, a method for protectively immunizing a hitman being against human immunodeficiency virus (HIV) by administering to the human being a vaccine consisting essentially of a first composition and a second composition, the first composition consisting essentialy of a live, attenuated viral vector encoding at least one HIV gp120 or fragment or derivative thereof and, optionally, at least one additional HIV polypeptide or fragment or derivative thereof, the second composition consisting essentially of at least one HIV gp120 polypeptide or fragment or derivative thereof and, optionally, at least one additional HIV polypeptide or fragment or derivative thereof; the method comprising the steps of administering the first composition
to the human being and subsequently administering to the human being at least one 
composition or combination of compositions selected from the group consisting of: the 
second composition alone; the first and second compositions, optionally separately or 
together as a single dose; at least one additional dose of the first composition followed by 
at least one dose of the second composition; the second composition followed by at least 
one additional dose of the first composition, optionally followed by at least one additional 
dose of the first and/or second composition; wherein a protective immune response 
against HIV is induced in the human being, is provided. In some embodiments, the 
compositions are administered together (e.g., at essentially the same time (e.g., 
simultaneously) to the same or different sites of a host) or separately (e.g., either in time 
or site of administration in the host).

In certain embodiments, at least one of the compositions comprises an amino acid 
sequence corresponding to that of a herpes simplex virus (HSV) (e.g., glycoprotein D 
(gD) leader sequence shown in Fig. 1). In certain embodiments, the HSV amino acid 
sequence may include, for example, KYALADASLKMADPNRPRGKDLPVLDDL (SEQ 
ID NO. 7), or a fragment thereof. In some embodiments, the HSV amino acid sequence 
may be that shown in the polypeptide "MN,mature" shown in Fig. 1 (SEQ ID 
NO.:3), or a fragment thereof. In some embodiments, the HSV amino acid sequence may 
be that shown in the polypeptide gd244 as shown in Fig. 1 (SEQ ID NO.:4), or a 
fragment thereof. In some embodiments, the gp120 amino acid sequence may be SEQ ID 
NO.: 5. In some embodiments, at least one of the compositions may comprise a 
polypeptide of any one or more of SEQ ID NOs. 3, 4, 5, or 7. By "comprise a 
polypeptide" is meant both a polypeptide per se and/or one encoded by a nucleic acid 
contained within an expression vector. Variations and derivatives of the polypeptides 
referred to herein may also be suitable, as could be determined by one of skill in the art.

In some embodiments, the first composition is administered repeatedly prior to at 
least one administration of the second composition, where the time between 
administrations is of sufficient length to allow for the development of an immune 
response within the human being. In some embodiments, the methods described herein 
comprise administering the vaccine is administered to a population of human beings such 
that at least about one-third of that population is protected from infection by HIV. In
some embodiments. The first composition is administered repeatedly prior to at least one administration of the second composition, with the time between administrations is of sufficient length to allow for the development of an immune response within the human being. In certain embodiments, administration of either or both the first and second compositions is via a route selected from the group consisting of mucosal, intradermal, intramuscular, subcutaneous, via skin scarification, intranodal, or mucratomoral. The dose of the compositions may vary, but in some embodiments, the amount of viral vector administered in each dose is the equivalent of about $10^7$ CCID$_{50}$ and the total amount of polypeptide administered in each dose is about 600 µg. In some embodiments, the viral vector may be a poxviral vector such as vaccinia, NYVAC, Modified Virus Ankara (MVA), avipox, canarypox, ALVAC, ALVAC(2), fowlpox, or TROVAC. In some embodiments, the viral vector may be ALVAC-HIV (vCPI521). The viral vector may comprise the nucleic acid sequence of SEQ ID NO. 1 or 5, for example. The second composition may be AIDSVAX* B/B or AIDSVAX* B/E. In some embodiments, the viral vector may be ALVAC-HIV (vCPI52.1) and the second composition may be AIDSVAX* B/E.

In certain embodiments, the HIV polypeptide or HIV gp120 is derived from an HIV virus selected from the group consisting of HIV-1, HIV-2, and HIV-3, wherein the first and second composition contain the same or different HIV polypeptides and / or gp120. The HIV-1 may be, for example, HIV-1 subtype A1, HIV-i subtype A2, HIV-1 subtype A3, HIV-1 subtype A4, HIV-i subtype B, HIV-1 subtype C, HIV-1 subtype D, HIV-1 subtype E, HIV-1 subtype F1, HIV-1 subtype F2, HIV-1 subtype G, HIV-1 subtype H, HIV-1 subtype J and HIV-1 subtype K. The HIV-2 may be, for example, HIV-2 subtype A, HIV-2 subtype B, HIV-2 subtype C, HIV-2 subtype D, and HIV-2 subtype E. The viral vector may encode, for example, at least one polypeptide selected from the group consisting of HIV gp120 MN 12-485, HIV gp120 A244 12-484, and HIV gp120 GNE8 12-477.

Where multiple HIV immunogens are used, the at least one additional HIV immunogen may be, for example, gag, pol, net, a variant thereof, and a derivative thereof. Thus, is some embodiments, the first or second composition additionally contain
at least one additional HIV immunogen selected from the group consisting of gag, the protease component encoded by pol, nef, a variant thereof, and a derivative thereof.

In preferred embodiments of the present invention, vectors are used to transfer a nucleic acid sequence encoding a polypeptide to a cell. A vector is any molecule used to transfer a nucleic acid sequence to a host cell. In certain cases, an expression vector is utilized. An expression vector is a nucleic acid molecule that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and/or control the expression of the transferred nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and splicing, if introns are present. Expression vectors typically comprise one or more flanking sequences operably linked to a heterologous nucleic acid sequence encoding a polypeptide. As used herein, the term operably linked refers to a linkage between polynucleotide elements in a functional relationship such as one in which a promoter or enhancer affects transcription of a coding sequence. Flanking sequences may be homologous (i.e., from the same species and/or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from more than one source), or synthetic, for example.

In certain embodiments, it is preferred that the flanking sequence is a transcriptional regulatory region that drives high-level gene expression in the target cell. The transcriptional regulatory region may comprise, for example, a promoter, enhancer, silencer, repressor element, or combinations thereof. The transcriptional regulatory region may be either constitutive, tissue-specific, cell-type specific (i.e., the region is drives higher levels of transcription in a one type of tissue or cell as compared to another), or regulatable (i.e., responsive to interaction with a compound such as tetracycline). The source of a transcriptional regulatory region may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequence functions in a cell by causing transcription of a nucleic acid within that cell. A wide variety of transcriptional regulatory regions may be utilized in practicing the present invention.

In some embodiments, derivatives of polypeptides, peptides, or polynucleotides incorporated into or expressed by the vectors described herein including, for example.
fragments and/or variants thereof may be utilized. Derivatives may result from, for example, substitution, deletion, or addition of amino acids or nucleotides from or to the reference sequence (e.g., the parental sequence). A derivative of a polypeptide or protein, for example, typically refers to an amino acid sequence that is altered with respect to the referenced polypeptide or peptide. A derivative of a polypeptide typically retains at least one activity of the polypeptide. A derivative will typically share at least approximately 60%, 70%, 80%, 90%, 95%, or 99% identity to the reference sequence. With respect to polypeptides and peptides, the derivative may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties. A derivative may also have "nonconservative" changes. Exemplary, suitable conservative amino acid substitutions may include, for example, those shown in Table 1:

<table>
<thead>
<tr>
<th>Original Residues</th>
<th>Exemplary Substitutions</th>
<th>Preferred Substitutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala</td>
<td>Val, Leu, Ile</td>
<td>Val</td>
</tr>
<tr>
<td>Arg</td>
<td>Lys, Gln, Asn</td>
<td>Lys</td>
</tr>
<tr>
<td>Asn</td>
<td>Gln</td>
<td>Gln</td>
</tr>
<tr>
<td>Asp</td>
<td>Glu</td>
<td>Glu</td>
</tr>
<tr>
<td>Cys</td>
<td>Ser, Ala</td>
<td>Ser</td>
</tr>
<tr>
<td>Gln</td>
<td>Asn</td>
<td>Asn</td>
</tr>
<tr>
<td>Glu</td>
<td>Asp</td>
<td>Asp</td>
</tr>
<tr>
<td>Gly</td>
<td>Pro, Ala</td>
<td>Ala</td>
</tr>
<tr>
<td>His</td>
<td>Asn, Gln, Lys, Arg</td>
<td>Arg</td>
</tr>
<tr>
<td>Ile</td>
<td>Leu, Val, Met, Ala, Phe, Norleucine</td>
<td>Leu</td>
</tr>
<tr>
<td>Leu</td>
<td>Norleucine, Ile, Val, Met, Ala, Phe</td>
<td>Ile</td>
</tr>
<tr>
<td>Lys</td>
<td>Arg, 1,4 Diamino-butyric Acid, Gln, Asn</td>
<td>Arg</td>
</tr>
<tr>
<td>Met</td>
<td>Leu, Phe, Ile</td>
<td>Leu</td>
</tr>
<tr>
<td>Phe</td>
<td>Leu, Val, Ile, Ala, Tyr</td>
<td>Leu</td>
</tr>
<tr>
<td>Pro</td>
<td>Ala</td>
<td>Gly</td>
</tr>
<tr>
<td>Ser</td>
<td>Thr, Ala, Cys</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
<td>Ser</td>
</tr>
<tr>
<td>Trp</td>
<td>Tyr, Phe</td>
<td>Tyr</td>
</tr>
<tr>
<td>Tyr</td>
<td>Trp, Phe, Thr, Ser</td>
<td>Phe</td>
</tr>
<tr>
<td>Val</td>
<td>Ile, Met, Leu, Phe, Ala, Norleucine</td>
<td>Leu</td>
</tr>
</tbody>
</table>

Other amino acid substitutions may be considered non-conservative. Derivatives may also include amino acid or nucleotide deletions and/or additions/insertions, or some combination of these. Guidance in determining which amino acid residues or nucleotides...
may be substituted, inserted, or deleted without abolishing the desired activity of the derivative may be identified using any of the methods available to one of skill in the art.

Derivatives may also refer to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide may include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide may encode a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide may be one modified by glycosylation, pegylation, biotinylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide. Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured. Percent identity can be measured both globally or locally. Examples of alignment algorithms known in the art for global alignments are ones which attempt to align every residue in every sequence, such as the Needleman-Wunsch algorithm. Local alignment algorithms are useful for dissimilar sequences that contain regions of similar sequence motifs within their larger sequence, such as the Smith-Waterman algorithm.
As mentioned above, this disclosure relates to compositions comprising recombinant vectors, the vectors per se, and methods of using the same. A "vector" is any moiety (e.g., a virus or plasmid) used to carry, introduce, or transfer a polynucleotide or interest to another moiety (e.g., a host cell). In certain cases, an expression vector is utilized. Art expression vector is a nucleic acid molecule containing a polynucleotide of interest encoding a polypeptide, peptide, or polynucleotide and also containing other polynucleotides that direct and/or control the expression of the polynucleotide of interest. Expression includes, but is not limited to, processes such as transcription, translation, and/or splicing (e.g., where introns are present).

Viral vectors that may be used include, for example, retrovirus, adenovirus, adeno-associated virus (AAV), alphavirus, herpes virus, and poxvirus vectors, among others. Many such viral vectors are available in the art. The vectors described herein may be constructed using standard recombinant techniques widely available to one skilled in the art. Such techniques may be found in common molecular biology references such as *Molecular Cloning: A laboratory Manual* (Sambrook, *et al.*, 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991, Academic Press, San Diego, CA), and *PCR Protocols: A Guide to Methods and Applications* (Innis, *et al.* 1990, Academic Press, San Diego, CA).

Suitable retroviral vectors may include derivatives of lentivirus as well as derivatives of murine or avian retroviruses. Exemplary, suitable retroviral vectors may include, for example, Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), SIV, BiV, HIV and Rous Sarcoma Virus (RSV). A number of retroviral vectors can incorporate multiple exogenous polynucleotides. As recombinant retroviruses are defective, they require assistance in order to produce infectious vector particles. This assistance can be provided by, for example, helper cell lines encoding retrovirus structural genes. Suitable helper cell lines include Psi2, PA317 and PA12, among others. The vector virions produced using such cell lines may then be used to infect a tissue cell line, such as NIB 3T3 cells, to produce large quantities of chimeric retroviral virions. Retroviral vectors may be administered by traditional methods (i.e., injection) or by implantation of a "producer cell line" in proximity to the target cell population (Culver, *et al.*, 1994, *Hum. Gene Ther.*).
5 (3): 343-79; Culver, K., et al., Cold Spring Mark Symp: Quant Biol., 59: 685-90); Oidfield, E., 1993, Hum. Gene Ther., 4 (1): 39-69). The producer cell line is engineered to produce a viral vector and releases viral particles in the vicinity of the target cell. A portion of the released viral particles contact the target cells and infect those cells, thus delivering a nucleic acid encoding an immunogen to the target cell. Following infection of the target cell, expression of the polynucleotide of interest from the vector occurs.


Alphavirus may also be used to express the immunogen in a host. Suitable members of the Alphavirus genus include, among others, Sindbis virus, Semliki Forest virus (SFV), the Ross River virus and Venezuelan, Western and Eastern equine encephalitis viruses, among others. Expression systems utilizing alphavirus vectors are described in, for example, U.S. Pat. Nos. 5,091,309; 5,217,879; 5,739,026; 5,766,602; 5,843,723; 6,015,694; 6,156,558; 6,190,666; 6,242,259; and, 6,329,201; WO 92/10578;


An exemplary suitable vector is MYVAC (vP866) which was derived from the Copenhagen vaccine strain of vaccinia virus by deleting six nonessential regions of the genome encoding known or potential virulence factors (see, for example, U.S. Pat. Nos. 5,364,773 and 5,494,807). The deletion loci were also engineered as recipient loci for the insertion of foreign genes. The deleted regions are: thymidine kinase gene (1K; J2R); hemorrhagic region (u; B13R+B14R); A type inclusion body region (AT1; A26L); hemagglutinin gene (HA; A56R); host range gene region (C7L-K1L); and, large summit, ribonucleotide reductase (ML). NYVAC is a genetically engineered vaccinia virus strain that was generated by the specific deletion of eighteen open reading frames encoding gene products associated with virulence and host range. NYVAC has been shown to be useful for expressing TAs (see, for example, U.S. Pat. No. 6,265,189). NYVAC (vP866), vP994, vCP205, vCP1433, placZH6K4Lreverse, pMPC6H6K3E3 and pC3H6F1VB were also deposited with the ATCC under the terms of the Budapest Treaty, accession numbers VR-2559, VR-2558, VR-2557, VR-2556, ATCC-97913, ATCC-97912, and ATCC-97914, respectively.

Another suitable virus is the Modified Vaccinia Ankara (MVA) virus which was generated by 516 serial passages on chicken embryo fibroblasts of the Ankara strain of vaccinia virus (CVA) (for review, see Mayr, A., et al Infection 3, 6-14 (1975)). It was shown in a variety of animal models that the resulting MVA was significantly avirulent (Mayr, A. & Danner, K. (1978) Dev. Biol. Stand. 41: 225.34) and has been tested in clinical trials as a smallpox vaccine (Mayr et al., ZS. Bakt. Hyg. 1. Abt. Org. B 167, 375-390 (1987), Stickl et al., Dtsch. med. Wschr. 99, 2386-2392 (1974)). MVA has also been

ALVAG-based recombinant viruses (i.e., ALVAC-I and ALVAC-2) are also suitable for use in practicing the present invention (see, for example, U.S. Pat. No. 5,756,103). ALVAC(2) is identical to ALVAC(l) except that ALVAC(2) genome comprises the vaccinia E3L and K3L genes under the control of vaccinia promoters (U.S. Pat. No. 6,130,066; Beaitie et al., 1995a, 1995b, 1991; Chang et al., 1992; Davies et al., 1993). Both ALVAC(l) and ALVAC(2) have been demonstrated to be useful in expressing foreign DNA sequences, such as TAs (Taitaglia et al., 1993 a,b; U.S. Pat. No. 5,833,975). ALVAC was deposited under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, USA, ATCC accession number VR-2547. Vaccinia virus host range genes (e.g., C18L, C17L, C7L, KI2, E3L, B4R, B23R, and B24D) have also been shown to be expressible in canarypox (e.g., U.S. Pat. No. 7,473,536).

Another useful poxvirus vector is TROVAC. TROVAC refers to an attenuated fowlpox that was a plaque-cloned isolate derived from the FP-1 vaccine strain of fowlpoxvims which is licensed for vaccination of 1 day old chicks. TROVAC was likewise deposited under the terras of the Budapest Treaty with the ATCC, accession number 2553.

"Non-viral" plasmid vectors may also be suitable for use. Plasmid DNA molecules comprising expression cassettes for expressing an immunogen may be used for
"naked DNA" immunization. Preferred plasmid vectors are compatible with bacterial, insect, and/or mammalian host cells. Such vectors include, for example, PCR-II, pCR3, and pcDNA3.1 (Invitrogen, San Diego, CA), pBSII (Stratagene, La Jolla, CA), pET15 (Novagen, Madison, WI), pGEX (Pharmacia Biotech, Piscataway, NJ), pEGFP-N2 (Clontech, Palo Alto, CA), pETL (BlieBadL Invitrogen), pDSR-alpha (PCT pub. No. WO 90/14363) and pFastBacDual (Gibco-BRL, Grand Island, NY) as well as Bloescr® plasmid derivatives (a high copy number COL1-based plasmid, Stratagene Cloning Systems, La Jolla, CA), PCR cloning plasmids designed for cloning Taq-amplified PCR products (e.g., TOPO® TA cloning® kit, PCR2.1® plasmid derivatives, Invitrogen, Carlsbad, CA).

Bacterial vectors may also be suitable for use. These vectors include, for example, Shigella, Salmonella (e.g., Darji, et al., Cell, 91: 765-775 (1997); Woo, et al. Vaccine, 19: 2945-2954 (2001)), Vibrio cholerae, Lactobacillus, Bacillus calmette guérin (BCG), and Streptococcus (e.g., WO 88/6626, WO 90/0594, WO 91/33157, WO 92/1796, and WO 92/2.1376). Many other non-viral plasmid expression vectors and systems are known in the art and could be used with the current invention.

Nucleic acid delivery or transformation techniques that may be used include DNA-ligand complexes, adenovirus-ligand-DNA complexes, direct injection of DNA, CaPO4 precipitation, gene gun techniques, electroporation, and colloidal dispersion systems, among others. Colloidal dispersion systems include macromolecule complexes, microparticles, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome, which are artificial membrane vesicles useful as delivery vehicles in vitro and in vivo. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, R., et al. Trends Biochem. Sci., 6: 77 (1981)). The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or oilier lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations. Examples of lipids useful in Liposome production include phosphatidyl compounds, such as
phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and disearoylphosphatidylcholine.


In other embodiments, it may be advantageous to combine or include within the compositions or recombinant vectors additional polypeptides, peptides or polynucleotides encoding one or more polypeptides or peptides that function as "co-stimulatory" components. Such co-stimulatory components may include, for example, cell surface proteins, cytokines or chemokines in a composition of the present invention. The co-stimulatory component may be included in the composition as a polypeptide or peptide, or as a polynucleotide encoding the polypeptide or peptide, for example. Suitable co-stimulatory molecules include, for instance, polypeptides that bind members of the CD28 family (i.e., CD28, ICOS; Hutloff, et al. Nature 1999, 397: 263-265; Peach, et al. J Exp Med 1994, ISO: 2049-2058) such as the CD28 binding polypeptides B7.1 (CD80; Schwartz, 1992; Chen et al, 1992; Ellis, et al. J. Immunol, 156(8): 2700-9) and B7.2 (CD86; Ellis, et al. J. Immunol, 156(8): 2700-9); polypeptides which bind members of

One or more cytokines may also be suitable co-stimulatory components or "adjuvants", either as polypeptides or being encoded by nucleic acids contained within the compositions of the present invention (Parmiani et al. *Immunol Lett* 2000 Sep 15; 74(1): 41-4; Berzofsky, et al. *Nature Immunol.* 1: 209-219). Suitable cytokines include, for example, interleukin-2 (IL-2) (Rosenberg, et al. *Nature Med.* 4: 321-327 (1998)), IL-

Chemokines may also be utilized. For example, fusion proteins comprising CXCL10 (IP-10) and CCL7 (MCP-3) fused to a tumor self-antigen have been shown to induce anti-tumor immunity (Bőthy, et al. Nature Biotech. 1999, 17: 253-258). The chemokines CCL3 (MIP-1α) and CCL5 (RANTES) (Boyer, et al. Vaccine, 1999, 17 (Supp. 2): S53-S64) may also be of use in practicing the present invention. Other suitable chemokines are known in the art.

It is also known in the art that suppressive or negative regulatory immune mechanisms may be blocked, resulting in enhanced immune responses. For instance, treatment with anti-CTLA-4 (Shrikant, et al. Immunity, 1996, 14: 145-155; Sutmuller, et al. J. Exp. Med, 2001, 194: 823-832), anti-CD25 (Sutmuller, supra), anii-CD4 (Matsui, et al. J. Immunol., 1999, 163: 184-193), the fusion protein IL13Ra2-Fc (Terähe, et al. Nature Immunol., 2000, 1: 515-520), and combinations thereof (i.e., anti-CTLA-4 and aoti-CD25, Sutmuller, supra) have been shown to upregulate anti-tumor immune responses and would be suitable in practicing the present invention.

An immunogen may also be administered in combination with one or more adjuvants to boost the immune response. Adjuvants may also be included to stimulate or enhance the immune response against the immunogen. Non-limiting examples of suitable adjuvants include those of the gel-type (i.e., aluminum hydroxide/phosphate ("alum adjuvants"), calcium phosphate, of microbial origin (saponin), dipeptide (MDP)), bacterial exotoxins (cholera toxin (CT), native cholera toxin summit 8 (CTB), E. coli labile toxin (LT), pertussis toxin (PT), Cpg oligonucleotides, BCG sequences, tetanus toxoid, monophosphoryl lipid A (MPL) of, for example, E. coli, Salmonella Minnesota, Salmonella typhimurium, or Shigella exseri), particulate adjuvants (biodegradable, polymer microspheres), immunostimulaory complexes (ISCOMs), oil-emulsion and
suitant-based adjuvants (Freund’s incomplete adjuvant (FIA), microfluidized emulsions (MF59, SAF), saponins (QS-21)), synthetic (muramyl peptide derivatives (murabutide, threony-MDP), nonionio block copolymers (L121), polyphosphazene (PCCP), synthetic polynucleotides (poly A:U, poly I:C), thalidomide derivatives (CC-4407/ACTIMID)), RIB-ligand, or polyaciide glycoside (PLGA) microspireres, among others. Fragments, homology derivatives, and fusions to any of these toxins are also suitable, provided that they retain adjuvant activity. Suitable mutants or variants of adjuvants are described, e.g., in WO 95/1721 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/3423 (Arg-9-Lys and Glu-129-Gly PT mutant). Additional LT mutants that can be used in the methods and compositions of the invention include, e.g., Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other suitable adjuvants are also well-known in the art.

As an example, metal h₃ salt adjuvants such alum adjuvants are well-known in the art as providing a safe excipient with adjuvant activity. The mechanism of action of these adjuvants are thought to include the formation of an antigen depot such that antigen may stay at the site of injection for up to 3 weeks after administration, and also the formation of antigen/metallic salt complexes which are more easily taken up by antigen presenting cells. In addition to aluminium, other metallic salts have been used to adsorb antigens, including salts of zinc, calcium, cerium, chromium, iron, and berilium. The hydroxide and phosphate salts of aluminium are the most common. Formulations or compositions containing aluminium salts, antigen, and an additional immunostimulant are known in the art. An example of an immunostimulant is 3-de-O-acylated monophosphoryl lipid A (3D-MPL).

Any of these components may be used alone or in combination with other agents, for instance, it has been shown that a combination of CD80, ICAM-1 and LFA-3 ("TRICOM") may potentiate anti-cancer immune responses (Hodge, et al. Cancer Res. 59; 5800-5807 (1999). Other effective combinations include, for example, IL-12 + GM-CSF (Aiders, et al. I Immunol, 158;3947-3958 (1997); Iwasaki, et al J. Immunol 158; 4591-4601 (1997)), IL-12 + GM-CSF + TNF-α (Ahiets, et al. Int. Immunol, 13; 897-908 (2001)), CD80 + IL-12 (Freund, et al. Int. J. Cancer, 85; 508-517 (2000); Rao, et al. supra), and CD86 + GM-CSF + IL-12 (Iwasakt, supra). One of skill in the art would be
aware of additional combinations useful in carrying out the present invention. In addition, the skilled artisan would be aware of additional reagents or methods that may be used to modulate such mechanisms. These reagents and methods, as well as others known by those of skill in the art, may be utilized in practicing the present invention.

Other agents that may be utilized in conjunction with the compositions and methods provided herein include anti-HIV agents including, for example, protease inhibitor, an HIV entry inhibitor, a reverse transcriptase inhibitor, and/or an anti-retroviral nucleoside analog. Suitable compounds include, for example, Agenerase (amprenavir), Combivir (Retrovir / Epivir), Crixivan (indinavir), Emtriva (emtricitabine), Epivir (3tc / lamivudine), Epzicom, Fortovase / lopinavir (saquinavir), Fuzeon (enfuvirtide), Hivid (ddc / zidovudine), Katetra (lopinavir), Lexiva (fosamprenavir), Norvir (ritonavir), Rescriptor (delavirdine), Retrovir / AZT (zidovudine), Reyatax (atazanavir, BMS-232632), Sostiva (efavirenz), Trizivir (abacavir / zidovudine / lamivudine), Truvada (Emtricitabine / Tenofovir DF), Videx (ddl / didanosine), Videx EC (ddl, didanosine), Viread (tenofovir disoproxil fumarate), Ziagen (abacavir). Other suitable agents are known to those of skill in the art. Such agents may either be used prior to, during, or after administration of the compositions and/or use of the methods described herein.

Administration of a composition of the present invention to a host may be accomplished using any of a variety of techniques known to those of skill in the art. The composition(s) may be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals (i.e., a "pharmaceutical composition"). The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of DNA, viral vector particles, polypeptide, peptide, or other drug candidate, for example. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods. The compositions are administered to a patient in a form and amount sufficient to elicit a therapeutic effect. Amounts effective for this use will depend on various factors, including for example, the particular composition of the vaccine regimen administered, the manner of administration, the stage and severity of the disease, the general state of
health of the patient, and the judgment of the prescribing physician. The dosage regimen for immunizing a host or otherwise treating a disorder or a disease with a composition of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods.

In general, recombinant viruses may be administered in compositions in a dosage amount of about $10^4$ to about $10^9$ pfu per inoculation; often about $10^8$ pfu to about $10^9$ pfu, or as shown in the Examples, $10^7$ to $10^8$ pfu. Higher dosages such as about $10^4$ pfu to about $10^9$ pfu, e.g., about $10^5$ pfu to about $10^6$ pfu, or about $10^9$ pfu to about $10^{10}$ pfu, or about $10^7$ pfu can also be employed. Another measure commonly used is ceil culture infective dose (CG D$_{50}$); suitable culture ranges for administration include about $10^3$, about $10^4$, about $10^5$, about $10^6$, about $10^7$, about $10^8$, about $10^9$, about $10^{10}$ CCID$_{50}$. Ordinarily, suitable dosage amounts of plasmid or naked DNA are about 1 µg to about 100 mg, about 1 mg, about 2 mg, but lower levels such as 0.1 to 1 mg or 1-10 µg may be employed. For polypeptide compositions (e.g., AIDSVAX compositions), a suitable amount may be 1-1000 µg. Without limiting the possible sub-ranges within that dosage range, particular embodiments may employ 5, 10, 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, and 1000 mg. A typical exemplary dosage of polypeptide may be, for example, about 50-250 pg, about 250-500 pg, 500-750 pg, or about 1000 pg of polypeptide. Low dose administration may typically utilize a dose of about 100 pg or less. High dose administration may typically utilize a dose of 300 pg or more. In referring to the amount of polypeptide in a dose, it is to be understood that the amount may refer to the amount of a single polypeptide or, where multiple polypeptides are administered, to the total amount of all polypeptides (e.g., 300 pg each of two polypeptides for a total administration of 600 pg). The AIDSVAX compositions described herein are typically but not necessarily administered in a total dosage of 200 pg or 600 pg (e.g., recombinant MN and GNE8 gp120, or recombinant MN and A244 gp120). "Dosage" may refer to that administered in a single or multiple doses, including the total of all doses administered.
Actual dosages of such compositions can be readily determined by one of ordinary skill in the field of vaccine technology.

The pharmaceutical composition may be administered orally, parentally, by inhalation spray, rectally, intranodally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term "pharmacologically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of a nucleic acid, polypeptide, or peptide as a pharmaceutical composition. A "pharmaceutical composition" is a composition comprising a therapeutically effective amount of a nucleic acid or polypeptide. The terms "effective amount" and "therapeutically effective amount" each refer to the amount of a nucleic acid or polypeptide used to observe the desired therapeutic effect (e.g., induce or enhance and immune response).

Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Suitable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution, among others. For instance, a viral vector such as a poxvirus may be prepared in 0.4% NaCl or a Tris-HCl buffer, with or without a suitable stabilizer such as lactogluconate, and with or without freeze drying medium. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglyeerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Pharmaceutical compositions may take any of several forms and may be administered by any of several routes. The compositions are administered via a parenteral route (e.g., intradermal, intramuscular, subcutaneous, skin scarification) to induce an immune response in the host. Alternatively, the composition may be administered directly into a tissue or organ such as a lymph node (e.g., intranodal) or tumor mass (e.g., intratumoral). Preferred embodiments of administrable compositions
include, for example, nucleic acids, viral particles, or polypeptides in liquid preparations such as suspensions, syrups, or elixirs. Preferred injectable preparations include, for example, nucleic acids or polypeptides suitable for parental, subcutaneous, intradermal, intramuscular or intravenous administration such as sterile suspensions or emulsions. For example, a naked DNA molecule and/or recombinant poxvirus may separately or together be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like. The composition may also be provided in lyophilized form for reconstituting, for instance, in isotonic aqueous, saline buffer. In addition, the compositions can be co-administered or sequentially administered with one another, other antiviral compounds, other anti-cancer compounds and/or compounds that reduce or alleviate ill effects of such agents.

As previously mentioned, while the compositions described herein may be administered as the sole active agent, they can also be used in combination with one or more other compositions or agents (i.e., other immunogens, co-stimulatory molecules, adjuvants). When administered as a combination, the individual components can be formulated as separate compositions administered at the same time or different times, or the components can be combined as a single composition. In one embodiment, a method of administering to a host a first form of an immunogen and subsequently administering a second form of the immunogen, wherein the first and second forms are different, and wherein administration of the first form prior to administration of the second form enhances the immune response resulting from administration of the second form relative to administration of the second form alone, is provided. Also provided are compositions for administration to the host. For example, a two-part immunological composition where the first part of the composition comprises a first form of an immunogen and the second part comprises a second form of the immunogen, wherein the first and second parts are administered together or separately from one another such that administration of the first form enhances the immune response against the second form relative to administration of the second form alone, is provided. The immunogens, which may be the same or different, are preferably derived from the infectious agent or other source of immunogens. The multiple immunogens may be administered together or separately, as a single or multiple compositions, or in single or multiple recombinant vectors.
instance, a viral vector encoding an immunogen may be initially administered and followed by one or more subsequent administrations with a second form of the immunogen (e.g., a polypeptide). The different forms may differ in either or both of the form of delivery (e.g., viral vector, polypeptide) or in the immunogens represented by each 6 rm. It is preferred that the forms, however, induce or enhance the immune response against a particular target (e.g., HIV-1). For instance, as shown herein, a viral vector encoding a viral antigen (e.g., HIV gp120) may be administered to a human being. This may then be followed by administration of the viral vector along with a polypeptide representing the same or a similar viral antigen (e.g., HIV gp120). For prime-boost applications (e.g., ALVAC-HIV and AIDSVAX™), ALVAC-HIV is typically administered in a 10^7 CCID_50 dosage (the “priming” dose), and then subsequently re-administered at the same or different dosage along with a suitable dosage (e.g., 600 µg total, the “boosting” dose) of polypeptide (e.g., AIDSVAX™ B/B or B/B). ALVAC-HIV is a preparation of live attenuated, recombinant canarypox virus (ALVAC(I)) expressing gene products from the HIV-1 env (clade E in vCP1521 and clade B in vCP205), gag (clade B), and protease (clade B) coding sequences (Fig. 2). Exemplary, non-limiting prime-boost combinations may include ALVAC-HIV (vCP205) and AIDSVAX™ B/B or ALVAC-HIV (vCP1521) and AIDS VAX™ B/E, as the HIV clades from which the gp120 immunogen is derived in those combinations are the same. Typically, both the priming and boosting doses are administered via the same route (e.g., intramuscular, intradermal) but the routes of administration may also be different. Typically, the priming and boosting doses are administered to different parts of the body, but the doses may also be administered to the same part of the body. “Along with” may mean that the two forms are administered as separate compositions, as part of a single composition, at separate sites of the body, or at the same site of the body, depending on the particular protocol. Variations of such exemplary dosing regimens may be made by those of skill in the art.

A kit comprising a composition of the present invention is also provided. The kit can include a separate container containing a suitable carrier, diluent or excipient. The kit may also include additional components for simultaneous or sequential-administration. In one embodiment such a kit may include a first form of an immunogen and a second
form of the immunogen. Additionally, the kit can include instructions for mixing or combining ingredients and/or administration. A kit may provide reagents for performing screening assays, such as one or more PCR primers, hybridization probes, and/or biochips, for example,

A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.

**EXAMPLES**

**Example 1**

**Immunological Compositions**

**X**,  **First composition**: viral vector

ALVAC-HIV is a preparation of live attenuated, recombinant canarypox virus (ALVAC(!)) expressing gene products from the HIV-1 em (clade E in vCP1521 and clade B in vCP205), transmembrane anchoring portion of gp4t (clade B:LAi), gag (clade B:LAi), and protease (clade B:LAf) coding sequences and cultured in chick embryo fibroblast cells. These vectors were generated by co-insertion of genes encoding HIV-1 gene products into the ALVAC(l) genome at the C6 insertion site using standard techniques (Fig. 2A). The HIV-1 sequences contained within ALVAC-HIV (vCP!521) are shown in Fig. 2B and SEQ ID N()S.:5 and 6. These sequences include: 1) the region of the em gene encoding the extracellular envelope gp120 moiety of TH023 strain of HIV-1 linked to the sequences encoding the HIV-1 transmembrane anchor sequence of gp4t (28 amino acids), under the control of the vaccinia virus H6 promoter; and, 2) the gag gene encoding the entire Gag protein, and a portion of the pol sequences of LAI strain of HIV-1 sufficient to encode the protease function, under the control of the same vaccinia virus promoter 13L.

ALVAC-HIV was produced by inoculation of the ALVAC-HIV working seed lot in primary chick embryo fibroblasts and cultivation in roller bottles. After viral amplification, the infected cells were harvested and disrupted by sonication and cell debris removed by centrifugation. An equal volume of stabilizer (lactoglutarate) was blended with the supernatant and the suspension filtered through a 4.5 μm membrane. The clarified suspension was filled into vials and stored at <-35°C. At this step, the
biological substance is the clarified harvest of the vaccine. This blend (final bulk product) was prepared and then filled and freeze dried. Immunoprecipitation analyses were performed using radio-labelled lysates derived from uninfected CEF cells or cells infected with either ALVAC(I) parental virus or ALVAC-HIV. Immunoprecipitation was performed using human serum derived from HIV-seropositive individuals. Results with anti-HIV demonstrated expression of gp120, the 55 kDa precursor Gag polypeptide, and intermediate and completely processed forms of Gag including the major capsid protein, p24 in ALVAC-HIV infected CEF cells but not from cells infected with ALVAC parental vims.

Regarding ALVAC-HIV (vCP1521X FACS) scan analyses with human anti-HIV antibody demonstrated expression of gp120 on the surface of infected HeLa, but not the parental virus. PCR amplification of the inserted sequences and those of ALVAC was performed. DNA analysis was performed by agarose gel electrophoresis followed by ethidium bromide staining to confirm the identity of the amplified fragments according to their molecular size. Restriction analysis was performed on viral DNA derived from ALVAC-HIV (vCP1521) infected cells to confirm proper insertion of the gpl20TM and gag expressing cassettes. The nucleotide sequence of inserted genes was confirmed by sequencing on the Working Seed Lot (passage 6).

ALVAC-HIV (vCP1521) genetic stability was confirmed by immunoplaque assay after several passages on CEF. Immunoplaque analysis consisted of detecting Env and Gag expression in viral plaques by monoclonal antibodies. Analysis was performed after 7 passages (i.e. at the production lot level) and after 10 passages (i.e. 3 passages beyond the production lot level).

ALVAC-HIV (vCP1521) was formulated as a lyophilized vaccine for injection and reconstituted with 1.0 mL of sterile sodium chloride solution (NaCl 0.4%) for a single dose. The composition of the vaccine after reconstitution with 1.0 mL NaCl 0.4% included ALVAC-HIV (vCP1521); \( \geq 10^6 \text{ ID}_{50} \) and excipients (TRIS-HCl buffer 10 mM, pH 9, 0.25 raL; stabilizer (laetoglomamate), 0.25 raL; freeze-drying medium, 0.50 mL; and NaCl, 4 mg). The appearance of the lyophilisate was homogeneous, white to beige; residual moisture was \( < 3\% \); reconstituting time was \( \leq 3 \) minutes; the appearance
after reconstitution was a limpid to slightly opalescent solution, colorless with possible presence of particles or filaments; pH between 7.0 and 8.0; osmolality between 350 to 700 mOsmol/kg; BSA content of <50 ng/dose; bacterial endotoxins content of ≤10 IU/dose. The ALVAC-HIV (vCP!521) was stored at 2-8 °C without freezing and administered within 2 hours of reconstitution. Prior to reconstitution, the vial was allowed to come to room temperature. Each vial was reconstituted with the diluent supplied, 1.0 mL 0.4% NaCl for administration by slow injection into the lyophilized ALVAC-HIV (e.g., using a 25 gauge, 5/8- inch needle). The vial was allowed to sit for approximately three minutes, and then gently swirled. The vial was then inverted and the contents withdrawn into a syringe.

B. Second composition: polypeptide

Recombinant gp120 is an envelope glycoprotein with apparent molecular mass of about 120,000 daltons. Approximately 50% of the molecular mass is accounted for by extensive glycosylation of the protein. AIDS VAX™ vaccines are highly purified mixtures of gp.120 proteins from HIV-1 produced by recombinant DNA procedures using Chinese hamsters ovary (CHO) cell expression. Molecular epidemiologic analyses of virus circulating in the US has documented polymorphisms occur at the major neutralizing epitopes of gp120. Analysis of breakthrough infections in Phase I and Phase II trials of MN gp120/HIV-1 revealed that most contained amino acid substitutions that differed from MN gp120/HIV-1 at epitopes important for virus neutralisation (specifically at the V2, V3 and C4 domains). After examining a variety of US strains, GNE8 was selected because amino acid sequences at sites know to be target of neutralizing antibodies differed from MN and possessed common polymorphisms that complemented MN at major neutralizing epitopes. Thus, an exemplary polypeptide composition is AIDS VAX™ B/B (VaxGen), which contains a bivalent polypeptide vaccine containing the HIV-1 type B epitopes MN recombinant glycoprotein (gp)120 (amino acids 12-485 of MN gp120) and GNE8 gp120 (amino acids 12-477 of GNE8 gp120) at a one-to-one ratio. Another exemplary polypeptide composition for use where subtypes B and E are prevalent (e.g., Thailand) is AIDS VAX™ B/E, which contains the subtype B antigen MN gp120 (as described above) and the subtype E antigen A244...
(CM244) recombinant glycoprotein 120 (amino acids 12-484 of A244 gp120) at a one-io-
one ratio. The subtype E antigen is derived from the A244 (CM244) strain of HIV-i, which is isolated from Chiang Mai in Northern Thailand and represents about 75% of the incident infections in intravenous drug users (IVDUs) in Bangkok. A244 rgp120 of HIV-1 is derived from a primary, macrophage or NS1 viral type and, like GNE8 rgp120/HIV-1, requires the chemokine receptor CCR5 to bind with CD4 cells.

In both AIDSVAX™ B/B and AIDSVAX™ B/E, gp120 of the MN, GNE8, or A244 strains are each expressed as an amino-terminal fusion protein with a 27 amino acids of the herpes simplex virus type 1 gD protein. The gD sequence facilitates gp120 expression and provides an epitope that can be used in a generic immunoaffinity purification process. The amino acid residues equivalent to the mature, native gp120 for each particular HIV-1 isolate utilized are; 12 to 485 for the MN isolate, 12 to 477 for the GNE8 isolate, and 12 to 484 for the A244 isolate.

The recombinant gpi 20 polypeptides are produced in genetically modified GHO cell line. The CHO cells secrete the rgp120/HIV-1 molecule into the culture medium, and the protein is purified by a generic purification process for gpi 20 that includes immunoaffinity chromatography. AIDSVAX™ bivalent vaccines are supplied as a sterile suspension in single-use glass vials. Each vial has a nominal content of 1 mL (300 µg/mL) of each rgp120/HIV-1 protein adsorbed onto a total of 0.6 mg aluminum hydroxide gel adjuvant.

**Example 2**

**Clinical Trial Design and Results**

A prime-boost immunization protocol using as the "prime" composition ALVAC-HIV (vCP1521) and the "boost" composition AIDSVAX® B/E was tested in a formal phase III clinical trial. The trial described here was a community-based, randomized (vaccine; placebo = 1:1), multicenter, double blind, placebo-controlled clinical trial conducted in Thailand. The primary objective of the study was to determine if vaccination with ALVAC-HIV (vCP1521) and AIDSVAX® B/E could prevent HIV infection in healthy Thai adults. Thus, infection rates, as well as plasma viral load and CD4⁺ T cell counts in volunteers developing HIV infection during the trial, were
assessed. The statistical assumptions of the study required that 16,000 persons enroll into the study. Intramuscular vaccinations (e.g., deltoid muscle) for each individual occurred during a 24-week period (0, 4, 12, 24 weeks). Following vaccination, the volunteers were tested for the presence of HIV in their plasma every 6 months for 3 years.

The "first composition" (ALVAC-HIV), as described in Example 1A above was initially administered to patients as the priming dose at months 0, 1, 3 and 6 (weeks 0, 4, 12 and 24). The "second composition" (AIDSVAX® B/E) was later administered at months 3 and 6 (weeks 12 and 24 as for ALVAC-HIV) as the boosting dose. ALVAC-HIV doses included approximately $10^7$ CCID$_{50}$. AIDSVAX® B/E doses included approximately 600 µg of polypeptide (300 µg of each of B and E). There was a 3 year follow-up with vaccine volunteers (Rerks-Ngarm, 2009, NEJM 361:2209). The trial design is summarized in Table 2, as shown below:

<table>
<thead>
<tr>
<th>Group</th>
<th>Number</th>
<th>Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>I</td>
<td>8,000</td>
<td>ALVAC</td>
</tr>
<tr>
<td>II</td>
<td>8,000</td>
<td>ALVAC-HIV</td>
</tr>
</tbody>
</table>

As shown in Fig. 3, the two-part composition was used in a prime-boost format to successfully vaccinate human beings with an efficacy of 31.2% (e.g., about one-third of the population). The population to whom a placebo was administered exhibited 74 HIV infections over the testing period, while those administered the ALVAC-HIV / AIDSVAX® B/E two-part composition ("vaccine") exhibited 51 HIV infections over the testing period. The difference in the number of HIV infections between the two groups was statistically significant ($p=0.039$). In patients that were infected by HIV after vaccination, neither the setpoint viral load nor mean CD4+ T cell counts were significantly different from placebo at 30 months post-vaccination. This is the first vaccine shown to reduce the risk of HIV infection in human beings compared to a
The observed vaccine efficacy was 31.2% (p = 0.0385, O'Brien-Fleming adjusted 95% CI 1.1, 52.1) using the Cox Proportional Hazard method. Thus, this is the first demonstration of a safe, efficacious vaccine that is capable of protecting human beings from infection by HIV.

It is to be understood that any reference to a particular range includes all individual values and sub-ranges within that range as if each were individually listed herein. All references cited within this application are incorporated by reference in their entirety. While the present invention has been described in terms of the preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations that come within the scope of the invention as claimed.

References


CLAIMS

What is claimed is:

1. A method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the human being at least one dose of a first composition comprising a viral vector encoding an HIV polypeptide or fragment or derivative thereof and subsequently administering to the human being at least one dose of a second composition comprising the HIV polypeptide or fragment or derivative thereof wherein a protective immune response directed against HIV is induced,

2. A method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the human being a vaccine consisting essentially of:

   a first composition and a second composition,

   the first composition consisting essentially of a live, attenuated viral vector encoding at least one HIV gp120 or fragment or derivative thereof and, optionally, at least one additional HIV polypeptide or fragment or derivative thereof,

   the second composition consisting essentially of at least one HIV gp120 polypeptide or fragment or derivative thereof and, optionally, at least one additional HIV polypeptide or fragment or derivative thereof;

the method comprising the steps of administering the first composition to the human being and subsequently administering to the human being at least one composition or combination of compositions selected from the group consisting of:

   the second composition alone;

   the first and second compositions, optionally separately or together as a single dose;

   at least one additional dose of the first composition followed by at least one dose of the second composition;

   the second composition followed by at least one additional dose of the first composition, optionally followed by at least one additional dose of the first and/or second composition;
wherein a protective immune response against HIV is induced in the human being.

3. The method of claim 1 or 2 wherein at least one of the compositions comprises an amino acid sequence corresponding to that of a herpes simplex virus (HSV).

4. The method of claim 3 wherein the HSV amino acid sequence comprises SEQ ID NO.: 7.

5. The method of claim 1 or 2 wherein one of the compositions comprises SEQ ID NO. 7.

6. The method of claim 1 or 2, farther comprising administering the vaccine is administered to a population of human beings and at least about one-third of that population is protected from infection by HIV.

7. The method of any one of claims 1-3, wherein the first composition is administered repeatedly prior to at least one administration of the second composition, with the time between administrations is of sufficient length to allow for the development of an immune response within the human being.

8. The method of claim 4, wherein the second composition is co-administered with the first composition.

9. The method of any one of claims 1-5, wherein administration of both the first and second compositions is via a route selected from the group consisting of mucosal, intradermal, intramuscular, subcutaneous, via skin scarification, intranodal, or intratumorai.

10. The method of any one of claims 1-6, wherein administration is at separate sites in the human being.

11. The method of any one of claims 1-7 wherein the amount of viral vector administered in each dose is the equivalent of about 10^7 CCID_{50} and the total amount of polypeptide administered in each dose is about 600 µg.

12. The method of any one of claims 1-11 wherein the viral vector is selected from the group consisting of retrovirus, adenovirus, adeno-associated virus (AAV), alphavirus, herpes virus, and poxvirus.

13. The method of claim 12 wherein the viral vector is a poxvirus.
14. The method of claim 13 wherein the poxvirus vector is selected from the group consisting of vaccinia, NYVAC, Modified Virus Ankara (MVA), avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TRVAC.

15. The method of claim 14 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

16. The method of any one of claims 1-15 wherein the HIV polypeptide or HIV gp120 is derived from an HIV virus selected from the group consisting of HIV-1, HIV-2, and HIV-3, wherein the first and second composition contain the same or different HIV polypeptides and/or gp120.

17. The method of claim 16 wherein the HIV-1 is HIV-1 subtype A, HIV-1 subtype A2, HIV-1 subtype A3, HIV-1 subtype A4, HIV-1 subtype B, HIV-1 subtype C, HIV-1 subtype D, HIV-1 subtype E, HIV-1 subtype F1, HIV-1 subtype F2, HIV-1 subtype G, HIV-1 subtype H, HIV-1 subtype J and HIV-1 subtype K.

18. The method of claim 16 wherein the HIV-2 is selected from the group consisting of HIV-2 subtype A, HIV-2 subtype B, HIV-2 subtype C, HIV-2 subtype D, and HIV-2 subtype E.

19. The method of any one of claims 1-18 further comprising administering a composition comprising at least one additional HIV immunogen selected from the group consisting of gag, pol, nef, a variant thereof, and a derivative thereof.

20. The method of any one of claims 1-19 wherein the first or second composition additionally contain at least one additional HIV immunogen selected from the group consisting of gag, the protease component encoded by pol, nef, a variant thereof, and a derivative thereof.

21. The method of any one of claims 1-20 wherein the viral vector encodes at least one polypeptide selected from the group consisting of HIV gp120 MN 12-485, HIV gp120 A244 12-484, and HIV gp320 GNE8 12-477.

22. The method of any one of claims 1-20 wherein the viral vector encodes at least HIV gp120 MN 12-485 and EN gp120 GNE8 12-477, or at least HIV gp12 MN 12-485 and HIV gp120 A244 12-484.

23. The method of any one of claims 1-22 wherein the viral vector is ALVAC-HIV (VCP1521).

36
24. The method of any one of claims 1-23 wherein the viral vector comprises the nucleic acid sequence of SEQ ID NO. 5.

25. The method of any one of date 1-24 wherein the second composition is AIDSVAX\textsuperscript{*} B/B or AIDSVAX\textsuperscript{®} B/E.

26. The method of my one of claims 1-25 wherein the viral vector is ALVAC-HIV (vCP1521) and the second composition is AIDSVAX\textsuperscript{*} B/E.
**FIGURE 1**

**gD leader sequence**

```
gD244  1 KALAGASLLKMADPHFRRGKIDLPVLCCGLLLVPYWKEFTLFCSADAKAK  
      2 KALAGASLLKMADPHFRRGKIDLPVLCCGLLLVPYWKEFTLFCSADAKAK  

Mn nature  1 EFEHNRWALTACVTPDNQGDLWTETFNWKNRMVYEGDNEFISL  
           2 EFEHNRWALTACVTPDNQGDLWTETFNWKNRMVYEGDNEFISL  

Mn244  31 WOGSLKPGVYIPGTYCINARLTKALRPWYHRAYNHYIQTDTDE  
      51 WOGSLKPGVYIPGTYCINARLTKALRPWYHRAYNHYIQTDTDE  

Mn nature  150 YHMC5FNTTLEDKHSDKVYLDDLPLCDPMDIENDKOGSFRILMCHTSVI  
           149 MNRC5NTEIDESSMKEHDDPLCDEIDNRETRVRLENKTSVI  

Mn244  190 HACRIPSFIPINTERPDAVILKCNKFPWCTOPFCKMYVTSQCTHG  
      197 HACRIPSFIPINTERPDAVILKCNKFPWCTOPFCKMYVTSQCTHG  

Mn nature  220 KVSTOQLLNGSLAEEVIQSELNLNANAKIYHKLYIYHTNHVN  
           227 KVSTOQLLNGSLAEEVIQSELNLNANAKIYHKLYIYHTNHVN  

Mn244  250 WRTSTFIEFGDVOYVTIDBRNHCMTGNTREKAKYTSKLETCH  
      257 WRTSTFIEFGDVOYVTIDBRNHCMTGNTREKAKYTSKLETCH  

Mn nature  280 TAKFKSFIQFIPSSGDDLETHMNFCNSFFYCNTEFLHNTCIANG...  
           287 TAKFKSFIQFIPSSGDDLETHMNFCNSFFYCNTEFLHNTCIANG...  

Mn244  310 IVPCMTKIKQGINGWQGDAQKMYAPPPLIIINICMTSIQGLLTH  
      317 IVPCMTKIKQGINGWQGDAQKMYAPPPLIIINICMTSIQGLLTH  

Mn nature  347 DGATNKHMHTPRFGGDMKONWNEFLKTYKVEVEFLPSVAFTHKERR  
           347 DGATNKHMHTPRFGGDMKONWNEFLKTYKVEVEFLPSVAFTHKERR  

Mn244  447 DGATTNKHMEIHFPRFGGDMKONWNEFLKTYKVEVEFLPSVAFTHKERR  
      447 DGATTNKHMEIHFPRFGGDMKONWNEFLKTYKVEVEFLPSVAFTHKERR  

Mn nature  477 YVOREXK  SEQ ID NO.: 2  
           477 YVOREXK  SEQ ID NO.: 3  
```
FIGURE 2

A. ALVAC-HIV Genome

B. Nucleotide sequence of the vCP1521 Insert
INTERNATIONAL SEARCH REPORT

International application No
PCT/US2010/049206

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K39/21 C07K14/035 C07K19/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of Box C.

0 See parent family annex.

* Special categories of cited documents:
* "A" document defining the general state of the art which is not considered to be of particular relevance
* "E" earlier document but published on or after the international filing date
* "L" document which may throw doubt on priority claimed by which is cited to establish the publication date of another document or other special reason (as specified)
* "O" document relating to an oral disclosure, use, exhibition or other means
* "P" document published prior to the international filing date but later than the priority date claimed
* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* "A" document member of the same patent family

Date of the actual completion of the international search
1 December 2010

Date of mailing of the international search report
09/12/2010

Name and mailing address of the SA
European Patent Office, P.B. 5418 Patentinfo 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040
Fax (+31-70) 340-3018

Authorized officer

Chapman, Rob

Form PCT/ISA210 (second sheet) (April 2006)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>JOHNSTON MARGARET I ET AL: &quot;Progress in HIV vaccine development&quot;, CURRENT OPINION IN PHARMACOLOGY, vol. 1, no. 5, October 2001 (2001-10), pages 504-510, XP009141671, ISSN: 1471-4892 the whole document</td>
<td>1-5, 12-17, 20-22</td>
</tr>
<tr>
<td>X</td>
<td>BELSHE ROBERT B ET AL: &quot;Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers&quot;, JOURNAL OF INFECTION DISEASES, vol. 183, no. 9, 1 May 2001 (2001-05-01), pages 1343-1352, XP009141810, ISSN: 0022-1899 the whole document</td>
<td>1-5, 12-17, 20-22</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>PENG BO ET AL: &quot;Repli cati ng rather than nonrepli cati ng adenovir us-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-til ter anti bodies&quot;, JOURNAL OF VIROLOGY, vol. 79, no. 16, August 2005 (2005-08), pages 10200-10209, XP009141664, ISSN: 0022-538X</td>
<td>1-5, 12</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No.</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>X</td>
<td>GOMEZ-ROMAN V RAUL ET AL: &quot;Vacci ne-el icited anti bodies mediate anti body-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SI Vmac251&quot;, JOURNAL OF IMMUNOLOGY, vol. 174, no. 4, 15 February 2005 (2005-02-15), pages 2185-2189, XP009141670, ISSN: 0022-1767 the whole document</td>
<td>1-5, 12</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No.</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>WO 0154701 A1</td>
<td>02-08-2001</td>
<td>AU 3306301 A</td>
</tr>
</tbody>
</table>